MedTrace Logo

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

NCT02038764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2018-08-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Placebo

Placebo

BIOLOGICAL

PF-06342674 Dose A

Multiple SC Doses

BIOLOGICAL

PF-06342674 Dose B

Multiple SC Doses

BIOLOGICAL

PF-06342674 Dose C

Multiple SC Doses

BIOLOGICAL

PF-06342674 Dose D

Multiple SC Doses

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-04
Primary Completion
2016-09-13
Completion
2016-09-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038764 on ClinicalTrials.gov